TAIWANPLUS
1.12.2021 08:41:10 CET | Business Wire | Press release
TaiwanPlus, a new global English-language video streaming service, has launched a Taiwan Cinema program with a selection of ten films that exemplify the diversity of Taiwan’s culture, peoples, and history. The most prominent collection is Ang Lee’s 'Father Knows Best' trilogy. Notably, this is the first time the films are available to be streamed online together. Director Lee’s strength in bringing together family members to create tension and tender comedic moments shine in this trio of PUSHING HANDS (1991), EAT DRINK MAN WOMAN (1994), and THE WEDDING BANQUET (1993).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130006205/en/
Renowned actor Sihung Lung acts as the consummate traditional Taiwanese father in roles that evoke the sweet bitterness of an aging man trying to bring each casts’ family together. Hailed for their unrestrained portrayals of Eastern family dynamics, the collection is available for free until December 31, 2021 to global viewers outside of the United States, Canada, Mexico, Germany, and France at TaiwanPlus.com via the website’s new Cinema section and downloadable TaiwanPlus mobile app.
In addition, seven other films will be presented until December 31, 2021 that will take viewers back to some of Taiwan’s greatest films outside of the Taiwan New Cinema Wave. “Movies are the best way to convey culture and emotions. Through these ten films of different eras and themes, we provide the audience a window into Taiwan’s culture and diversity.” says Joanne Tsai, TaiwanPlus CEO.
In addition to Ang Lee’s renowned films, the program is showcasing films directed by Chung Mong-hong, who recently won Best Narrative Feature and Best Original Screenplay for THE FALLS (2021) at this year's Golden Horse Awards. The After Death duo that brings us to edgier contemporary Taiwanese films that dare to dive into darker narratives. THE FOURTH PORTRAIT (2010) follows the story of a son left behind after the death of his father while in SOUL (2013), the mysterious collapse of a young chef leads to a terrifying spiritual possession in the mountains.
A trio of restored films include two cult favorite black and white films from the Taiwan Hollywood era of the 1960s-- THE FANTASY OF DEER WARRIOR (1961) and VENGEANCE OF THE PHOENIX SISTERS (1968) along with WHEEL OF LIFE (1983), an anthology helmed by King Hu that features three main characters reincarnating into the same twisted love triangle in each segment.
Rounding out the series are two documentaries. In SMALL TALK (2016) by Huang Hui-chen, a 20 year film in the making where the filmmaker attempts to confront and reconcile painful past memories with her mother, a lesbian Taoist priestess. Meanwhile, in ARCHIVING TIME (2019), viewers follow a group of film preservation staff from the Taiwan Film and Audiovisual Institute as they work to preserve crumbling reels of film the world has yet to see.
Watch Free @https://tw.plus/twxgh
View source version on businesswire.com: https://www.businesswire.com/news/home/20211130006205/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom